The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Comparative effects of chronic angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade on cardiac remodeling after myocardial infarction in the rat.
Abstract
BACKGROUND: After myocardial infarction, the noninfarcted left ventricle develops reactive hypertrophy associated with a depressed coronary flow reserve, myocardial interstitial fibrosis, and reduced capillary density. The present study investigated the comparative cardiac effects of chronic angiotensin-converting enzyme (ACE) inhibition and selective angiotensin II type 1 receptor (AT1) blockade in the rat model of myocardial infarction and failure. METHODS AND RESULTS: Seven days after coronary ligation (MI), rats were randomized to enalapril (n = 8; 500 micrograms.kg-1.d-1), losartan (n = 9; 3 mg.kg-1.d-1), or placebo (n = 8) and treated for 6 weeks. Sham-operated rats (n = 10) served as controls. Coronary blood flow was measured with radiolabeled microspheres during baseline and maximal coronary dilation induced by dipyridamole (2 mg.kg-1.min-1 over 10 minutes). Right and left ventricular (LV) weight was increased in infarcted rats compared with sham-operated animals and enalapril- and losartan-treated MI rats. Minimal LV and right ventricular coronary vascular resistance was increased in MI rats but normalized with enalapril and losartan (LV:sham, 8.9; MI-placebo, 12.7; MI-enalapril, 9.2; MI-losartan, 8.8 mm Hg.mL-1.min-1.g-1, all P < .05 versus MI-placebo). Interstitial fibrosis determined from perfusion-fixed hearts was increased in infarcted rats but reduced by both enalapril and losartan. Myocardial capillary density improved with enalapril and losartan. In separate groups treated as above, plasma and tissue ACE activity was determined and demonstrated significantly higher ACE activity in noninfarcted LV tissue of MI-placebo rats compared with sham (0.64 vs 0.27 nmol.mg protein-1.min-1, P < .05). Enalapril and losartan reduced LV ACE activity (0.39 and 0.29 nmol.mg protein-1.min-1, P < .05 versus MI-placebo). CONCLUSIONS: The present study demonstrates that both chronic ACE inhibition and AT1 receptor blockade (1) reduces cardiac hypertrophy, (2) restores minimal coronary vascular resistance in postinfarction reactive hypertrophy, and (3) attenuates the development of myocardial interstitial fibrosis in the noninfarcted LV. These results suggest that inhibition of generation of angiotensin II and AT1 receptor blockade are equally effective in preventing important features of ventricular remodeling after myocardial infarction.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pfeffer, M. A., Braunwald, E., Moyé, L. A., Basta, L., Brown, E. J., Cuddy, T. E., Davis, B. R., Geltman, E. M., Goldman, S., Flaker, G. C., et al. (1992) · New England Journal of Medicine · doi:10.1056/nejm199209033271001 · Cited by 5,911
Spectrophotometric assay and properties of the angiotensin-converting enzyme of rabbit lung
Cushman, D. W., & Cheung, H. S. (1971) · Biochemical Pharmacology · doi:10.1016/0006-2952(71)90292-9 · Cited by 2,625
Garg, U. C., & Hassid, A. (1989) · Journal of Clinical Investigation · doi:10.1172/jci114081 · Cited by 2,155
Effect of Captopril on Progressive Ventricular Dilatation after Anterior Myocardial Infarction
Pfeffer, M. A., Lamas, G. A., Vaughan, D. E., Parisi, A. F., & Braunwald, E. (1988) · New England Journal of Medicine · doi:10.1056/nejm198807143190204 · Cited by 1,103
Density and composition of mammalian muscle
Méndez, J., & Keys, A. (1960) · Metabolism · Cited by 802
Pfeffer, M. A., Pfeffer, J. M., Steinberg, C., & Finn, P. (1985) · Circulation · doi:10.1161/01.cir.72.2.406 · Cited by 718
Remodeling of the rat right and left ventricles in experimental hypertension.
Brilla, C. G., Pick, R., Tan, L. B., Janicki, J. S., & Weber, K. T. (1990) · Circulation Research · doi:10.1161/01.res.67.6.1355 · Cited by 674
Yusuf, S., Pepine, C. J., Garces, C., Pouleur, H., Rousseau, M., Salem, D., Kostis, J., Benedict, C., Bourassa, M., & Pitt, B. (1992) · The Lancet · doi:10.1016/0140-6736(92)92889-n · Cited by 666
Fishbein, M. C., Maclean, D., & Maroko, P. R. (1978) · PubMed · Cited by 462
Mulvany, M. J., Hansen, O. K., & Aalkjaer, C. (1978) · Circulation Research · doi:10.1161/01.res.43.6.854 · Cited by 460
Cited by
The pathogenesis of cardiac fibrosis
Kong, P., Christia, P., & Frangogiannis, N. G. (2014) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-013-1349-6 · Cited by 1,567
Frangogiannis, N. G. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvaa324 · Cited by 1,229
Molecular and Cellular Mechanisms of Angiotensin II-Mediated Cardiovascular and Renal Diseases
Kim, S., & Iwao, H. (2000) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01434-0 · Cited by 983
Cardiac fibrosis: Cell biological mechanisms, molecular pathways and therapeutic opportunities
Frangogiannis, N. G. (2019) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2018.07.001 · Cited by 841
Diop-Frimpong, B., Chauhan, V. P., Krane, S., Boucher, Y., & Jain, R. K. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1018892108 · Cited by 733
“Fortunately, long-term losartan therapy after myocardial infarction is not associated with a reduction in antifibrotic properties (54).”
BackgroundTGF-?1 and angiotensin networking in cardiac remodeling
ROSENKRANZ, S. (2004) · Cardiovascular Research · doi:10.1016/j.cardiores.2004.04.030 · Cited by 683
Pathophysiology of Myocardial Infarction
Frangogiannis, N. G. (2015) · Comprehensive Physiology · doi:10.1002/cphy.c150006 · Cited by 618
Ishiyama, Y., Gallagher, P. E., Averill, D. B., Tallant, E. A., Brosnihan, K. B., & Ferrario, C. M. (2004) · Hypertension · doi:10.1161/01.hyp.0000124667.34652.1a · Cited by 564
Counter-regulatory renin–angiotensin system in cardiovascular disease
Paz Ocaranza, M., Riquelme, J. A., García, L., Jalil, J. E., Chiong, M., Santos, R. A. S., & Lavandero, S. (2020) · Nature Reviews Cardiology · doi:10.1038/s41569-019-0244-8 · Cited by 561
Extracellular Matrix Remodeling in Heart Failure: A Role for De Novo Angiotensin II Generation
Weber, K. T. (1997) · Circulation · doi:10.1161/01.cir.96.11.4065 · Cited by 557
Infarct scar: a dynamic tissue
Sun, Y. (2000) · Cardiovascular Research · doi:10.1016/s0008-6363(00)00032-8 · Cited by 510
Pathophysiological Role of Angiotensin II Type 2 Receptor in Cardiovascular and Renal Diseases
Matsubara, H. (1998) · Circulation Research · doi:10.1161/01.res.83.12.1182 · Cited by 478
Rohde, L. E., Ducharme, A., Arroyo, L. H., Aikawa, M., Sukhova, G. H., Lopez-Anaya, A., McClure, K. F., Mitchell, P. G., Libby, P., & Lee, R. T. (1999) · Circulation · doi:10.1161/01.cir.99.23.3063 · Cited by 437
Tiret, L., Ducimetière, P., Bonnardeaux, A., Soubrier, F., Poirier, O., Ricard, S., Cambien, F., Marques-Vidal, P., Evans, A., Kee, F., et al. (1994) · The Lancet · doi:10.1016/s0140-6736(94)92268-3 · Cited by 416
Fibroblasts in the Infarcted, Remodeling, and Failing Heart
Humeres, C., & Frangogiannis, N. G. (2019) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2019.02.006 · Cited by 410
Silvestre, J.-S., Heymes, C., Oubénaïssa, A., Robert, V., Aupetit-Faisant, B., Carayon, A., Swynghedauw, B., & Delcayre, C. (1999) · Circulation · doi:10.1161/01.cir.99.20.2694 · Cited by 380
Takemoto, M., Egashira, K., Usui, M., Numaguchi, K., Tomita, H., Tsutsui, H., Shimokawa, H., Sueishi, K., & Takeshita, A. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119156 · Cited by 325
Angiotensin II Has Multiple Profibrotic Effects in Human Cardiac Fibroblasts
Kawano, H., Do, Y. S., Kawano, Y., Starnes, V., Barr, M., Law, R. E., & Hsueh, W. A. (2000) · Circulation · doi:10.1161/01.cir.101.10.1130 · Cited by 312
Healing after myocardial infarction
ERTL, G., & FRANTZ, S. (2005) · Cardiovascular Research · doi:10.1016/j.cardiores.2005.01.011 · Cited by 300
Myocardial repair/remodelling following infarction: roles of local factors
Sun, Y. (2008) · Cardiovascular Research · doi:10.1093/cvr/cvn333 · Cited by 295
Characteristics of 9194 Patients With Left Ventricular Hypertrophy: The LIFE Study
Dahlöf, B., Devereux, R. B., Julius, S., Kjeldsen, S. E., Beevers, G., de Faire, U., Fyhrquist, F., Hedner, T., Ibsen, H., Kristianson, K., et al. (1998) · Hypertension · doi:10.1161/01.hyp.32.6.989 · Cited by 294
The Mechanistic Basis of Infarct Healing
Frangogiannis, N. G. (2006) · Antioxidants & Redox Signaling · doi:10.1089/ars.2006.8.1907 · Cited by 288
Ocaranza, M. P., Godoy, I., Jalil, J. E., Varas, M., Collantes, P., Pinto, M., Roman, M., Ramirez, C., Copaja, M., Diaz-Araya, G., et al. (2006) · Hypertension · doi:10.1161/01.hyp.0000237862.94083.45 · Cited by 273
Cavalera, M., Wang, J., & Frangogiannis, N. G. (2014) · Translational Research · doi:10.1016/j.trsl.2014.05.001 · Cited by 267
Angiotensin II Activates Collagen I Gene Through a Mechanism Involving the MAP/ER Kinase Pathway
Tharaux, P.-L., Chatziantoniou, C., Fakhouri, F., & Dussaule, J.-C. (2000) · Hypertension · doi:10.1161/01.hyp.36.3.330 · Cited by 173
Metadata
- Authors
- Schieffer, B., Wirger, A., Meybrunn, M., Seitz, S., Holtz, J., Riede, U. N., & Drexler, H.
- Venue
- Circulation
- Published
- 1994-05
- Volume
- 89
- Issue
- 5
- Pages
- 2273-2282
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2024162107
- Cited by
- 420
- References
- 37
- FWCI
- 19.47
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.